Xiangming Fang Haibo Mou Xinxin Ying Xuehua Hou Luo Wang Ying Wu Naimeng Yan Lijie Guo Qin Liao
10.3389/fonc.2022.1024677
Front Oncol
2022 Dec 22;12:1024677.
her2 amplification mucinous ovarian carcinoma next-generation sequencing pyrotinib trastuzumab
CC BY
https://pubmed.ncbi.nlm.nih.gov/36620566/
Case Reports
PMC9815494
36620566
Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in HER2-amplification recurrent mucinous ovarian carcinoma
2022